The committee considered 5 separate charges against Dr Radev, relating to his treatment of a Yorkshire Terrier and Shih Tzu cross called Pickles at a Vets4Pets veterinary practice in Oxford between 5 October 2015 and 1 November 2015. The charges related to Dr Radev failing to provide adequate and/or appropriate care to the animal and failure to keep detailed clinical records.
After hearing the evidence from Dr Radev and the complainant, the College submitted that it wished to withdraw charges 1(i) and 1(ii) on the basis of insufficient evidence. In addition, Dr Radev had already admitted charges: 1(iii)(b), 1(iv)(d), 1(v), 4(i)(a) and 4(ii)(a) but denied the remaining charges. Of these remaining charges the Committee found charges 1(iv)(a), 2(i), 2(iv), 3(i) and 3(ii) proven with the rest not being proven.
The charges admitted or found proven were that Dr Radev:
(1) On 5 October 2015, failed to provide adequate and/or appropriate care and/or treatment to Pickles, more particularly in that he:
(iii) Failed to offer and/or undertake adequate investigations into Pickles’ condition, more particularly in that he failed to offer and/or undertake:
(b) urine tests;
(iv) Failed to put in place and/or document an adequate management plan for Pickles, more particularly in relation to:
(a) adequate direction and/or advice regarding a review of Pickles’ condition within a clearly defined number of days;
(d) collection of urine at home for analysis on review at the practice;
(v) Having noted that he suspected renal disease, prescribed meloxicam when the same was contraindicated for dogs with renal disease;
(2) On 28 October 2015, failed to provide adequate and/or appropriate care and/or treatment to Pickles, more particularly in that he:
(i) Failed to take and/or record an adequate history from Mrs Pancott in relation to Pickles’ condition and/or clinical signs since 5 October 2015;
(iv) Failed to provide adequate direction and/or advice regarding a date for a review of Pickles’ condition within a clearly defined number of days;
(3) On 30 October 2015, having been informed that Mrs Pancott had telephoned the practice with concerns about Pickles, including blood in the faeces;
(i) Failed to note the matter in Pickles’ medical records;
(ii) Failed to take sufficient steps to obtain more information from Mrs Pancott or to ensure that Mrs Pancott was advised to seek veterinary attention for Pickles in relation to her concerns;
(4) On 1 November 2015, failed to provide adequate and/or appropriate care and/or treatment to Pickles, more particularly in that he:
(i) Failed to interpret the blood tests adequately and/or take appropriate and adequate action in relation to the results of those blood tests, more particularly with regards to:
(a) blood glucose;
(ii) Failed to offer and/or undertake adequate investigations into Pickles’ condition, more particularly in that he failed to:
(a) offer and/or undertake urine tests.
In considering these charges the Disciplinary Committee found that only charge 4(ii)(a) – namely the failure to correctly interpret and act upon the results of a blood glucose test – amounted to serious professional conduct with the rest not passing the threshold of disgraceful conduct in a professional respect. The Committee did not consider that in addition the cumulative effect of all the proven charges taken together amounted to serious professional misconduct.
In relation to the cumulative effect of all the proven charges Professor Alistair Barr, chairing the Committee and speaking on its behalf, said: "The Committee noted that Dr Radev had made errors in relation to one patient but on four separate occasions. These were, for the most part, individual failures at the lower end of the scale of seriousness. Taking into account all of the failings, the Committee in its judgement did not consider that the nature and number of errors and the period of time over which they took place justified a cumulative finding of disgraceful conduct."
In considering the sanction for Dr Radev the Committee took into account a number of mitigating circumstances including the fact that Dr Radev had undertaken suitable training and development in the areas in which he made mistakes, had demonstrated good insight into his conduct and had made some open and frank admissions early on in proceedings. It also considered that the one charge that was found to be serious professional misconduct was a single, isolated mistake linked to Dr Radev’s inexperience.
Professor Barr said: "The Committee considered that taking ‘no further action’ was appropriate and proportionate having considered the history of the case, the Committee’s overall findings and the good reports of Dr Radev’s performance in the two years since the matter which had led to the finding of disgraceful conduct in a professional respect."
The decision to take no further action was also influenced by the length of time it had taken the charges to be heard by the Committee, the positive character references about Dr Radev from professional colleagues and the fact he was unlikely to repeat such conduct in the future.
Vets Now has published a response to the RCVS DC ruling in which Munhuwepasi Chikosi, a locum working for the company, was struck off for delaying an emergency OOH home visit.
The response is available in full here: http://www.vets-now.com/news/?item=4191
Merial has announced the launch of Oncept IL-2, the first veterinary immunotherapeutic product in Europe for the management of cancer in pets.
Described by the company as a true breakthrough in the field of veterinary oncology, Oncept IL-2 is an adjunct immunotherapy for feline fibrosarcoma.
Merial says the product is based on recombinant canarypox vector technology it developed collaboratively with veterinary oncologists, and which is used in several of its vaccines, including PUREVAX FeLV and PUREVAX Rabies.
Oncept IL-2 is indicated for cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, in order to reduce the risk of relapse and to increase the relapse-free interval. It should be used in addition to surgery and radiotherapy.
Kevin Whelan, Merial's Technical Manager said: "Following injection around the tumour surgery site, the recombinant canarypox vector virus enters the cat's cells, which then produce interleukin-2. The presence of this cytokine stimulates an anti-tumour immune response by a variety of mechanisms, including the induction of T-lymphocytes and natural killer cells."
In a field efficacy trial, a treatment course with Oncept IL-2 (consisting of 6 subcutaneous administrations in the tumour bed over a 7-week period), as an adjunct to surgery and radiotherapy, was shown to significantly reduce the risk of relapse and to increase the time to relapse.
The product is available in packs of 6 doses, which is sufficient for a treatment course. Please contact your local Merial Territory Manager for further information or email oncept@merial.com
The new ingredients include pomegranate, which Virbac says helps clean and control dental plaque1,2,3, Inulin to balance intestinal microflora and reduce foul smelling intestinal gas emissions4,5, and Erythritol to freshen breath with a cooling and anti-plaque effect6,7.
Dan Johnson, Product Manager at Virbac, said: "Bad breath is a common complaint by pet owners8, but some pets do not accept any brushing, especially cats, so Vet Aquadent FR3SH is an easy way to help control bad breath and plaque at home
"The benefit of water additives as part of passive homecare is already recognised by the WSAVA Dental Guidelines, meaning Vet Aquadent FR3SH plays a trusted and proven role in any proactive dental care routine".
For information, contact your Virbac Territory Manager.
References
Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager, said: "Arti-Cell Forte is the first 'ready-to-use' stem cell-based product to be licensed in any veterinary species, and the only stem cell treatment to contain induced cells, representing a significant leap forward in both stem cell therapies and medicine as a whole.
"Arti-Cell Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage. Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses¹."
"This makes Arti-Cell Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease."
Arti-Cell Forte is available direct from Boehringer Ingelheim to veterinary practitioners.
It needs to be stored at ultra-low temperatures to maintain its two year shelf life from manufacture, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately prior to injecting.
The company is providing full training on storage and administration via face-to-face CPD at practice meetings or specific CPD events*.
For more information, contact your local territory manager or ring Boehringer's Technical Services Team on 01344 746957, or email vetenquiries@boehringer-ingelheim.com
Reference
For the research, Miele commissioned independent market research firm Sapio to interview 1000 pet owners and 100 UK-based vet practices.
Veterinary practices have good reason to worry about complaints: the research showed that 89% of veterinary clients would be quick to tell others if they were dissatisfied with any aspect of the practice or care received. 63% said they would air their grievances on an online review site and 60% said they'd share their views on social media.
Those figures appear to be borne out by the fact that only 10% of vets said they had not seen any negative comments online about their practice.
Interviews with pet owners also found that the top five factors to affect a practice's reputation were: standard of care, a clean and hygienic environment, good customer service, the cost of treatment and waiting times, in that order.
64% of vets agreed that practice hygiene has become increasingly important with cleanliness of staff uniforms and waiting rooms among the first things that customers notice.
The suitably spruce Sam Bailey (pictured right), Sales & Marketing Director for the Professional division of Miele said: "Vet practices are increasingly coming under the same online scrutiny as hotels and restaurants and are being judged on everything from customer service through to staff appearance and waiting times.
"As our research results show, vets are already concerned about their reputations and it’s not just customer service and care outcomes that matter to pet owners, they also have high expectations when it comes to the practice environment too and are looking at cleanliness, hygiene and staff appearance.
"Through our network of approved partners we are working with more and more vet practices throughout the UK to ensure their on premise laundries not only meet WRAS regulations but also support their standards on hygiene, infection control and cleanliness."
The Mayor of Loughton, Councillor Philip Abraham, officially opened the Vets4Pets Loughton veterinary surgery inside Pets at Home at the Epping Forest Shopping Park, before enjoying a guided tour of the bright and modern facility.
Cheryl, who stars in the BBC’s children’s TV show The Pet Factor, said: "It’s fantastic to be able to open the doors to Vets4Pets Loughton and reach a landmark number of practices for the group.
"The opening event gave us chance to meet new clients, and welcome them to the practice."
Cheryl qualified in 2009 and is also a joint venture partner at Vets4Pets Chadwell and Newbury Park in Ilford.
Nick, who qualified in 2008, is also joint venture partner at Newbury Park, Romford, Beckton and Dagenham.
Nick said: "I have always been interested in caring for pets and have several dogs and cats at home.
"I love being a veterinary nurse and I’m delighted to have another opportunity from Vets4Pets to open my fifth practice.
"Once again the process to open a practice has been easy and we’ve had brilliant support on all aspects from Vets4Pets.
"I’m now looking forward to welcoming pets and their owners to Vets4Pets Loughton and providing the highest standard of veterinary care to the area’s pets."
The new practice will create five new jobs, with two vets, veterinary nurse, two pet care assistants and a receptionist.
Chief executive of the Pets at Home Vet Group, Andrei Balta, said: "Cheryl and Nick are two great advocates for the veterinary profession and we’re delighted they are part of the group.
"Wherever we have opened, pet owners have responded enthusiastically to our state-of-the-art practices and convenient opening hours.
"The joint venture model we operate across our practices provides the support vets and vet nurses need to run their businesses.
"It allows them to focus on what they really love, looking after the health of animals, while the support team helps with other areas including marketing, HR and business strategy."
Zoetis, maker of Zylexis, is highlighting a new review published in Veterinary Immunology and Immunopathology, which has concluded that immune-modulators may provide a valuable contribution to the reduction of some equine respiratory diseases
The study reviewed the immune-modulators Parapoxvirus ovis and Propionbacterium acnes for the prevention of respiratory disease and other infections in the horse.
Parapoxvirus ovis (iPPVO) and Propionibacterium acnes (P.acnes) are currently used in equine medicine as immune-modulators for prophylactic treatment or adjunct to conventional therapy in order to improve immune defences, to prevent or treat infectious diseases. Their mode of action relies on a non-antigen-specific interaction with the innate and/or adaptive immune responses. iPPVO stimulates and regulates cytokine secretion by a number of leucocytes, while P. acnes acts primarily through activation of macrophages.
The review, conducted by Romain Paillot of the Animal Health Trust, Centre for Preventive Medicine, Newmarket, examined current scientific literature and reports on the use of immune-modulators in horses, particularly for the prevention or treatment of equine respiratory disease.
Stress factors such as weaning, transport and co-mingling predispose horses to infection and increase susceptibility to respiratory pathogens such as Streptococcus zoopidemicus and EHV-1/4. In the past 15 years iPPVO has been tested against several equine infectious respiratory diseases.
The review examined the results of studies on the beneficial use of iPPVO to limit the severity of respiratory infectious diseases in young horses, one of which evaluated the use of iPPVO for protection in yearlings exposed by contact challenge to EHV-1 or EHV-42,3,4. Yearlings treated with iPPVO were co-mingled with horses experimentally infected with EHV-1 and the trial was repeated with horses infected with EHV-4. Horses treated with iPPVO showed a 40% reduction in disease severity in the EHV-1 study and a 61% reduction in the EHV-4 study.
Further studies showed significantly increased frequency of recovery in horses with clinical signs of respiratory disease that had been treated with P. acnes. The decrease in disease severity was also significantly improved in the treated groups5,6.
Romain Palliot concluded: "Non-specific immune-modulators such as iPPVO or P. acnes may not provide protection against direct infection or transmission of respiratory pathogens but they seem to contribute to the reduction of the disease severity, subsequently reducing the frequency of complications and improving the rate of recovery."
Ubroseal is licenced for the prevention of new intramammary infections throughout the dry period. In cows considered likely to be free of sub-clinical mastitis, the product can be used on its own in dry cow management and mastitis control.
Boehringer's veterinary adviser, Kath Aplin said: "Ubroseal features a flexi-cap to reduce the risk of teat canal damage and its unique longer plunger makes application more ergonomic and significantly easier for the farmer."
The launch coincides with the publication of a statement by an expert group convened by Boehringer1 which recommends the administration of an internal teat sealant at drying off to all cows on all farms.
For more information, contact: vetenquiries@boehringer-ingelheim.com.
Thiamacare contains 10 mg/ml thiamazole, which is double the concentration of Thyronorm, for a lower dose volume.
Animalcare highlights research which shows that 87.4% of owners prefer liquid medications for their cat1, and that cats find liquid presentations more palatable2.
James Beaumont from Animalcare said: "With the lowest dose volume available, we believe Thiamacare will make the medical management of this condition easier through improved cat acceptance and better owner compliance."
Thiamacare's dosing syringe is marked with a single scale in 1.25 mg increments to facilitate precise dosing in response to total T4 measurement values. The scale does not need converting when switching from other brands or formulations.
Animalcare has developed a range of supporting materials to encourage the use of Thiamacare as the preferred choice for feline hyperthyroid medical management. They include social posts and a post-prescription leaflet to help veterinary teams support owners, particularly through the stabilisation phase post-diagnosis.
A short webinar offering top tips for treating feline hyperthyroidism from feline Specialist Dr Caney will also be available later in October. These resources will all be available at www.the-pac.co.uk.
The study1, which was conducted in collaboration with Plymouth University, sought to find out what influences owners to buy a flat-faced breed, and once this decision has been made, how they go about acquiring a puppy. The study surveyed owners of the top 10 most popular Kennel Club registered breeds in the UK, to compare how influences upon breed choice and purchasing processes differed between owners of flat-faced breeds and popular longer-faced breeds.
Appearance was found to be the number one reason owners purchase flat-faced breeds, attracted by their large, round, wide-set eyes, and flat rounded faces. However, such characteristics are linked with lifelong respiratory, eye and skin problems, and a reduced lifespan compared with longer-faced breeds.
Key influencing factors associated with the choice of a brachycephalic breed included:
When it came to buying a flat-faced dog, owners were:
Dr Rowena Packer, lead author of the study and Research Fellow at RVC, said: "With their small size and baby-like features, some people cannot resist the looks of a brachycephalic dog. With growing evidence that these breeds are faced with a range of chronic and severe health conditions directly linked with their appearance, it is of huge concern that many people drawn to these breeds prioritise a dog’s looks over their long-term health and wellbeing.
"Potential puppy buyers attracted to the appearance of these breeds should seriously consider whether they are emotionally and financially prepared to take on a breed with high risks of health complications, and consider whether alternative, lower-risk breeds would better fit their lifestyle."
Co-author of the study and Associate Professor of Animal Welfare at Plymouth University, Dr Mark Farnworth, said: "Owners must be aware that as puppy-buyers, they are consumers, and their choices affect not only the health of the puppy they purchase, but also the health of the breed more widely. If owners do not follow recommended processes when purchasing a puppy, for example those set out in BVA AWF & RSPCA ‘Puppy Contract’, unscrupulous breeders will be kept in business, and continue to profit from the breeding and sale of unhealthy dogs. Without consumer awareness, breed health improvements are not possible and the overall health of these breeds will likely decline."
Paula Boyden, Dogs Trust Veterinary Director said: "The increased popularity of breeds such as Pugs, French Bulldogs and English Bulldogs is a huge welfare concern, particularly as this research indicates that the health of the breed was not a major consideration for potential puppy buyers. Many people mistakenly believe that the breathing sounds these breeds often make are endearing traits, rather than an indication of respiratory problems associated with their conformation. Dogs Trust urges anyone thinking of getting a puppy to look beyond the appearance of a breed, understand the impact on health, research the seller and buy responsibly."
Researchers say that the French Bulldog is set to become the most registered dog in 2017, overtaking the Labrador Retrievers’ 27-year reign at the top. The study therefore makes a number of recommendations, including:
Photo: Wikipedia CC BY-SA 3.0 Credit: Cristorresfer
Neuro orthopaedic veterinary surgeon Noel Fitzpatrick has been having a busy old time: hot on the heels of his world-first procedure to implant a prosthetic hip and femur in an American Bulldog comes the news that he has now fitted a cat with titanium prosthetic paws in another world-first.
Oscar the cat was minding his own business, basking in the late summer sun, when a passing combine harvester chopped off his hind paws.
Unlucky.
However, Oscar's luck turned when his veterinary surgeon, Peter Howarth from St Saviour in Jersey, referred owners Kate and Mike Nolan to Fitzpatrick Referrals to investigate the possibility of giving Oscar a pair of prosthetic paws.
Kate said: "We had to do a lot of soul-searching and our main concern has always been whether this operation would be in Oscar's best interests and would give him a better quality of life". Having decided it would, the Nolans asked Noel to go ahead. And so he came to give the two-year-old cat a pair of new artificial feet in a single, three-hour surgical procedure - something he says has never been done before by any team anywhere in the world.
The revolutionary design of the feet uses custom-made implants to 'peg' the ankle to the foot and mimics the way in which deer antler bone grows through skin. These pegs, or ITAPs (intraosseous transcutaneous amputation prosthetics), were first developed by a team from University College London led by Professor Gordon Blunn, Head of the Centre for Bio-Medical Engineering at UCL's Institute of Orthopaedics and Musculoskeletal Science. Working in partnership with UCL, Fitzpatrick has pioneered the use of these weight-bearing prosthetic implants.
During the operation, the veterinary surgical team had to insert the ITAPs by drilling into one of the ankle bones in each of the back legs - an extremely delicate feat, which could have fractured the ankle joint before the procedure had even begun, and even more challenging because it had to be performed twice. These artificial implants which are attached to the bone at an amputation site are coated with hydroxyapatite, which encourages bone cells to grow onto the metal. The skin then grows over the special umbrella at the end of the ITAP to form a resilient seal against bacteria and potentially fatal infections. The ITAP itself protrudes through the bone and skin, allowing the custom-built artifical paws to be attached securely. Click here to see x-rays and other case photos in the VetSurgeon media gallery.
Following successful surgery in November last year, the focus of the veterinary team has turned to the slow process of rehabilitation and helping Oscar to learn to walk again - firstly using external scaffolding anchored to the tibia to protect the new implants until the ITAPs integrated into the bone and the skin grew onto the ITAP. Remarkably Oscar was trying to stand within a day of the operation and despite some problems with infection that had to be overcome, in less than four months Oscar could stand and bear weight equally on all four limbs. He has since been fitted with a series of prototype new paws to ensure the best possible long term fit.
What makes this procedure so complicated is that Oscar's feet were severed at the junction of the tarsus and metatarsus. Noel said: "The real revolution with Oscar is because we have put a piece of metal and a flange into which skin grows into an extremely tight bone, with very narrow tolerances in the region of nanometres, rather than millimetres. We have then successfully managed to get the bone and skin to grow into the implant and we have developed an exoprosthesis that allows this implant to work as a see-saw on the bottom of an animal's limbs to give him effectively normal gait. Oscar can now run and jump about as cats should do.
Noel Fitzpatrick and the team at Fitzpatrick Referrals are the focus of a new six part documentary series: The Bionic Vet to be broadcast on BBC 1 at 10.45 pm every Wednesday starting on 30 June 2010. The programmes will focus on the multi million pound state-of-the-art vet practice in Surrey as well as the ways in which Noel is pioneering revolutionary new surgical techniques.
Tablets are divisible into 15mg increments to enable accurate titration of dosing, come blister-packed to facilitate dispensing and are liver flavoured to help with compliance.
TVM says that in a first for a phenobarbital generic, Soliphen has proven bioequivalence to the market leading brand, which provides the reassurance of staying on-label when switching from the leading brand is necessary or desirable.
William Peel, Product Manager at TVM UK, said: "Phenobarbital is the only veterinary licensed drug for use in idiopathic and structural epilepsy, benefiting a large proportion of epileptic dogs with an improvement in seizure frequency. As a result, phenobarbital is a mainstay of treatment in epilepsy cases. With Soliphen, we have developed a cost-effective, easier and more accurate solution."
Soliphen is supported with a range of materials for use in practice, including owner booklets on epilepsy and in practice guidelines for the management of status epilepticus and chronic seizure control.
For more information, speak to your local TVM-UK Territory Manager, email: help@tvm-uk.com, visit: www.tvm-uk.com or call: 0800 0385868.
Fort Dodge Animal Health has launched PropoClear, a short-acting, intravenous general anaesthetic for dogs and cats.
The company believes that PropoClear, based on novel lipid-free micro-emulsion technology, will deliver significant clinical benefits over conventional lipid-based propofol emulsions, and will also deliver increased cost-effectiveness and convenience to practices.
PropoClear is indicated for use as a short-acting general anaesthetic for procedures lasting up to five minutes. It is also indicated for the induction and maintenance of general anaesthesia using incremental doses and for the induction of anaesthesia where maintenance is provided by inhalation.
According to Fort Dodge, PropoClear's unique lipid-free, nano-emulsion formulation and its inclusion of antimicrobial preservatives provide the following key benefits to practices:
Dr Jo Murrell, Department of Clinical Veterinary Science, Division of Companion Animals, the University of Bristol, said: "With currently available lipid-based propofol formulations unused drug should be discarded immediately once the vial has been opened leading to drug wastage or the potential for bacterial contamination of the remaining solution if this regulation is ignored. The new lipid-free propofol formulation, which also contains antimicrobial preservatives, overcomes this limitation and will provide significant clinical benefits in terms of the 28 day shelf life once broached."
Matthew Rowe, Marketing Manager for Companion Animals at Fort Dodge, said: "In developing PropoClear, it was our goal to deliver an anaesthetic product with the same proven efficacy as the existing solution but which offered significant benefits in terms of enhanced safety, cost and convenience.
"PropoClear contains the same concentration of the established active molecule and follows familiar guide dose protocols to ensure ease of use. We have been encouraged by the positive feedback received during product trials and believe the significant advantages its offers, both clinically and financially, to practices in challenging times, will ensure its rapid adoption by veterinary practices across the UK."
Alphazium TT contains alphalactalbumin and magnesium, which, according to the company, targets the three main neurological pathways involved in the regulation of mood and emotional balance.
TVM says Alphazium TT is highly palatable, so it can be administered as a treat, making the process stress free for veterinary staff, pets and pet owners.
TVM UK’s product manager Will Peel said: "Behavioural problems are becoming increasingly common in cats and dogs and are these problems are likely to get worse with pet owners going back to work as lockdown measures lift, which could cause further stress and anxiety in pets.
"Alphazium TT can help owners address these problems whilst being highly palatable – therefore also reducing the stress of tablet administration all-round."
For more information and support materials, visit: https://www.tvm-uk.com/alphaziumtt/2520/ or contact your TVM UK Territory Manager.
Licensed for use from 6 weeks of age - and in pregnant and lactating bitches and queens - Evicto provides adulticidal, larvicidal and ovicidal flea protection, which can also help to control environmental flea infestations in areas where the pet has access. It also treats ear mites, biting lice, intestinal roundworms, sarcoptic mange in dogs, intestinal hookworms in cats and can be used to prevent heartworm disease with monthly administration.
Evicto is presented in packs of 4 pipettes which are transparent so owners can see that the full dose has been applied. The company also highlights that with Evicto pets can be bathed 2 hours after treatment without loss of efficacy.
Claire Lewis, Product Manager at Virbac said: "We are pleased to add Evicto to our award-winning range of parasite protection products.
"Evicto can also be used concurrently with Milpro, making it the perfect product partnership."
Evicto is available from the veterinary wholesalers now.
For information, speak to your Virbac Territory Manager.
Suvaxyn PRRS MLV offers the earliest piglet vaccination from the first day of age, securing immunity before the risk period which lasts until the end of the fattening. Pig protection is established 28 days after vaccination, and lasts for 26 weeks after vaccination in fattening pigs, and 16 weeks after vaccination in gilts and sows. Zoetis says the vaccine reduces viremia and nasal shedding of the virus.
Monica Balasch, Associate Director, Global Biologicals Development at Zoetis said: "In Europe, Porcine Reproductive and Respiratory Syndrome is known for severe impacts on reproduction including lowering birth rates, increasing abortion, stillbirth, mummified, as well as weak live-born piglets, and death.
"In clinical studies conducted with Suvaxyn PRRS MLV, we found excellent results vaccinating pigs from the first day of age. It is safe to be used as the earliest protection in piglets, and to protect the whole herd against PRRS, as it is also safe for use in gilts and sows.
"The new vaccine represents a flexible alternative to allow for new customized PRRS control programs developed by veterinarians for producers."
Alvaro Aldaz, Director, Commercial Development and Innovation, Swine, at Zoetis said: "We are excited to bring this innovative vaccine to Europe. Suvaxyn PRRS MLV has been developed using a very innovative vaccine technology which brings swine veterinarians a new advanced PRRS control tool.
"As well reducing viremia, nasal shedding and lung lesions in fattening pigs, the vaccine has been proven to overcome maternal immunity, which increases the efficacy of the vaccine when given to piglets during the first days of life. Additionally, it allows veterinarians for use PRRS mass vaccination within the claim; mass vaccination has become more and more popular in several European countries."
Suvaxyn PRRS MLV is a veterinary vaccine that contains a European PRRS virus strain (Genotype 1) that has been grown and attenuated in a uniquely modified cell line developed by Zoetis.
Jay Calvert, Research Director, VMRD Global Biologicals Research at Zoetis said: "Suvaxyn PRRS MLV is safe based on true loss of virulence, and not based on a temporary reduction in ability to replicate in macrophage cells in the lung of the pig."
Zoetis says the efficacy of Suvaxyn PRRS MLV is supported by a comprehensive program of clinical studies reviewed by the European Medicines Agency and included in the regulatory procedure approved by the European Commission in August 2017.
The European public assessment report is available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/veterinary/004276/WC500235212.pdf
The company says the most common side effects with Suvaxyn PRRS MLV (which may affect more than one in 10 pigs) are a short-lived increase in body temperature (0.5°C on average and up to 1.4°C individually) within four days of vaccination, and in sows local reactions in the form of swellings which resolve without treatment within five to 32 days.
The RCVS Disciplinary Committee has suspended a London-based veterinary surgeon from the Register for six months, having found that her falsification of clinical records amounted to serious professional misconduct.
At the two-day hearing, Dr Nicola Ersilova was charged with, and admitted to, three separate incidences of false and dishonest clinical record keeping following her treatment of a collapsed cat, whilst working at Vets Now in Thamesmead, London.
The Committee heard how Dr Ersilova had suspected that Lafite the cat, belonging to Mr Yingzhan Xiao, had been poisoned, so administered fluids and treated her with Lidocaine. A lay colleague, who was assisting with the treatment, subsequently observed Dr Ersilova standing staring at the cat, which had stopped breathing, then leaving the room to go and speak to Mr Xiao. The lay colleague's evidence confirmed to the Committee that Lafite's heart was still beating at this point, and that Dr Ersilova was then heard telling Mr Xiao that Lafite had died while being treated. The lay colleague later discovered that Dr Ersilova had listed calcium gluconate on Mr Xiao's bill and not Lidocaine and, when she questioned the entry, Dr Ersilova told her she was worried about getting into trouble if she had listed Lidocaine.
Whilst reporting these irregularities to the senior veterinary surgeon at Vets Now, the lay colleague noticed that Dr Ersilova had also written "CPR unsuccessful" in the notes, although she was certain CPR (cardiopulmonary resuscitation) had not been attempted.
During a subsequent Vets Now investigation, Dr Ersilova admitted adding this false information concerning Lidocaine, calcium gluconate and CPR, saying during interview that she was aware it was serious professional misconduct and that she was prepared to take the consequences. Vets Now reported the matter to the RCVS.
The Committee considered that all evidence before it fully supported the charges against Dr Ersilova, that her conduct was clearly dishonest, and that her actions were inexcusable, especially for someone as experienced as she was. It stated that a veterinary surgeon's duty to make only truthful and accurate records was so manifest and well known to veterinary surgeons that there could be no real excuse to make such false, misleading and dishonest entries.
The Committee highlighted the comment by Dr Ersilova that she knew she had done something wrong but did not expect her colleague to report her, as providing no explanation, or excuse, for doing something which she knew to be wrong.
A number of submissions were made to the Committee in mitigation, including that Dr Ersilova had admitted her dishonesty to both her employers and the Committee; had an otherwise unblemished record over 22 years of practice; had received no immediate financial gain by her actions; and, did not cause any animal suffering.
Accepting these submissions, the Committee nevertheless felt it needed to balance them against other factors. Dr Ersilova's decision to falsify the records was premeditated and had not been taken without an opportunity for full reflection. There were numerous entries in the RCVS Code of Professional Conduct that highlighted the importance of professional integrity and accuracy, and, given the importance which the Code attached to the duty of veterinary surgeons to be truthful and honest in all their dealings with their clients, the Committee found Dr Ersilova's conduct to be "most reprehensible".
Speaking on behalf of the Disciplinary Committee, its Vice-Chairman, Professor Sheila Crispin, said: "It is of great importance that the public should be able to retain confidence in the honesty and integrity of members of the profession. Both the public and other members of the profession must be entitled to rely on the truthfulness of what a veterinary surgeon has written in the clinical records of any animal [they have] treated.
"It is [our] decision that the sanction of suspension adequately reflects the seriousness of the [Dr Ersilova's] conduct. The sanction imposed is ... the most appropriate to inform the profession how seriously such dishonest conduct will be taken, because such conduct clearly brings the profession into disrepute and ... cannot and will not be tolerated."
The Committee then concluded that the least period of suspension that could be justified was one of six months.
A wild golden eagle, one of only 442 breeding pairs, has died after being confiscated from a falconry expert who was nursing the animal back to health, and placed in the care of the RSPCA instead.
Roy Lupton, a falconer from Kent, saved the eagle in November last year, after it sustained injuries fighting a friend's bird. According to newspaper reports, Mr Lupton was given permission by the Scottish Executive to take the bird back to his premises in Kent to nurse it back to health. He planned to release the bird in the spring and claims he told Defra of his plans. Nevertheless, on May 5th, his premises were raided by Kent police, a Defra official and an official from the RSPB.
Despite his protests, the bird was seized and taken to the RSPCA's Mallydam wildlife centre in Sussex. Mr Lupton was questioned by police and the case passed to the Crown Prosecution Service. It was later dropped.
Meanwhile, Mr Lupton was allowed to visit the bird at the wildlife centre. He said: "I was horrified by what I saw. The RSPCA was keeping the bird on a concrete floor, which is bad for its talons, and there was leaf mould on the roof of the room, which can cause lung infections in golden eagles."
Mr Lupton was later allowed to take the animal home. However, its condition had deteriorated badly, and on June 17th he took the animal to see avian vet Neil Forbes. Sadly, nothing could be done, and the animal died hours later.
In his autopsy report, Neil said that the bird was kept in inappropriate conditions while in the care of the RSPCA and was "not provided with good practice in terms of husbandry". He added: "Whilst I cannot be certain the bird’s death was a direct result of the Defra seizure and the period of RSPCA care, certainly the stress effect (suppressing the immune system), the persistent systemic infection from the time of leaving the RSPCA care, does indicate a very high likelihood of a causative link between the period of care and the bird’s subsequent death."
Veterinary surgeons have named their top new veterinary products of 2012 in a survey carried out by CM Research.
As part of the research, 343 vets working in UK practice were asked what they considered to be the best new product of 2012. Their answers were unprompted, and they were only allowed to mention one product or service. For this reason, some vets voted for products that were launched earlier than 2012. The full results were as follows:
Hill's y/dAn iodine restrictive hyperthyroid management food launched by Hill's Pet Nutrition in May 2012 won with an overwhelming 31% of the votes. www.hillspet.co.uk
Cardalis (CEVA Animal Health)Launched towards the end of 2012, CEVA's combined ACE inhibitor / spirolactone for heart failure in dogs scored a creditable 9.6% of mentions. www.ceva.co.uk
Seresto (Bayer Animal Health)Bayer's 8-month flea and tick collar came third with 6% of the votes. www.seresto.com.
Caninsulin Vetpen from MSDLaunched in July 2012, this new insulin delivery pen for Caninsulin is designed to improving dosing accuracy, consistency and ease of use. The user-friendly pen design is said to improve initial pet owner acceptance and on-going compliance.
Atopica Cat (Novartis Animal Health)Novartis launched Atopica Cat, an oral version of its treatment for chronic allergic dermatitis, at the start of 2012. www.itchfreepet.co.uk
Comfortis (Elanco)Launched in 2011, Comfortis is a novel oral flea adulticide for dogs which kills adult fleas rapidly for a month. www.comfortis.com
Nobivac Myxo RHD (MSD)The first vaccine to combine 12 months protection against both myxomatosis and rabbit haemorrhagic disease within a single inoculation. It is a non-adjuvanted vaccine which, according to MSD, delivers greater simplicity of protocol and enhanced disease protection.
Cimalgex (Vétoquinol)Launched towards the end of 2011, Vetoquinol's 2nd generation Cox-2 inhibitor is said by the company to be very well tolerated, have an excellent efficacy profile and be very easy to use, meaning that Cimalgex allows veterinary patients to benefit from pain relief in situations where clinicians would have been worried about the risks versus the benefits of prescribing a NSAID for pain management.
Activyl (MSD)MSD's novel flea spot-on is the first to work by bioactivation, only becoming an insecticide after being ingested by the flea, thus minimising owner's exposure to insecticides. Said to be effective against the other stages of the flea life cycle, too. www.activyl.co.uk
RevitaCAM (Abbott)RevitaCAM is the first and only veterinary NSAID (meloxicam) with oromucousal delivery. www.revitacam.co.uk.
Metacam for cats (Boehringer Ingelheim)Boehringer extended its Metacam 0.5 mg/ml Oral Suspension for Cats range with the launch of a 30ml bottle size in July. www.metacam.co.uk.
Zuprevo (MSD)MSD's antibiotic to combat bovine respiratory disease (BRD) was launched in the third quarter of 2011. www.zuprevo.com
V-Gel (Docsinnovent)V-gel was the first ever species-specific supraglottic airway device (pictured top right), currently available for cats and rabbits. Billed as the latest ground breaking technology for a safer anaesthesia, easier breathing and avoiding damage to the throat and trachea; a safer alternative to ET tubes. www.docsinnovent.com
Onsior (Novartis Animal Health)The tissue-selective oral and injectable Cox-2 inhibiting NSAID from Novartis was actually launched back in 2009.
Certifect (Merial)Merial's flea and tick spot-on for dogs was launched by Ray Mears in the UK in February 2012. www.certifect.co.uk
Calmex (VetPlus)Somewhat controversial when it made its first appearance in 2011, Calmex is a feed to help dogs and cats that may experience behavioural problems as a result of their environment or situations that may cause anxiety or fear. More info.
Comfortan (Dechra)The first licensed methadone for dogs was launched by Eurovet towards the end of 2011, before it was acquired by Dechra in May 2012. www.dechra.co.uk
Hill's Vet EssentialsHill's vet-exclusive petfood range is designed to meet essential dietary needs at every life stage. More info.
Trocoxil (Pfizer)Trocoxil, Pfizer's NSAID for canine osteoarthritis was remarkable for its once monthly dosage regime, when launched back in 2009.
VerafloxBayer launched its next generation fluoroquinolone antimicrobial for bacterial infections in cats and dogs at the end of 2011
YumoveYumove is a joint support supplement from Lintbells, containing glucosamine and chondroitin. More information.
The new maternity policy will offer enhancement at 100% of full pay for 10 weeks, and 50% of full pay for a further 10 weeks, without any clawback provision should mothers decide not to return to CVS after their leave.
As part of the Time To Change Pledge, CVS will submit a plan for introducing evidence-based interventions and policy to help its employees work in ways that promote positive mental wellbeing.
CVS's plan includes the appointment of 250 Wellbeing Champions who will be trained in first aid for mental health. The company also plans to roll out further training on managing stress and mental health issues for line managers in 2020.
Richard, pictured right, said: "We are proud to be the first major veterinary employer to sign the Time to Change Pledge. The CVS wellbeing working party have made much progress in the last 12 months delivering our plan which has been formalised through participating in the Time to Change pledge.
"We recognise that the pressures in our industry are significant and unique, and that there’s more work to do. We remain committed as a company and wellbeing working party to changing the way we all think and act about mental health in the workplace for the better."
Dermot Costello, a Shropshire practitioner, has been suspended by the RCVS Disciplinary Committee for 10 weeks after he admitted being dishonest with a client and falsifying records about the treatment of her dog.
Mr Costello faced four charges against him:
At the outset of the hearing, Mr Costelloe, a partner at a veterinary practice in Market Drayton, Shropshire, admitted all heads of charge against him.
Scruffy had been brought to Mr Costelloe for a consultation on 27 October 2014. He carried out a physical examination and arranged for radiographs and routine blood tests while also prescribing anti-inflammatory tablets for spondylosis. Scruffy was brought back to the practice on 30 October 2014 following the deterioration of her condition. Further assessment took place and an abdominal scan was arranged for the next day. She stayed at the practice overnight, but died at some point during the night of 30 to 31 October 2014.
A telephone call between Mrs Green and Mr Costelloe took place shortly after 8am on 31 October during which he told her that "they had struggled with Scruffy all night" and that, as they were speaking, Scruffy was on oxygen and struggling to breathe.
After Mrs Green said she wanted to come to the practice to be with her dog, Mr Costelloe told her to wait and that he would call her back in two minutes. He did so and told her Scruffy had died five minutes ago, when in fact she had died at some point between 11pm on 30 October and 8am on 31 October.
Mr Costelloe continued the deception at meetings with Mrs Green on 31 October and 19 November 2014 and she was given the falsified clinical records on 4 December 2014. Another meeting took place on 14 January 2015 where Mr Costelloe finally admitted his deception to her. This resulted in Mrs Green submitting a formal complaint to the RCVS on 23 February 2015. He admitted his deception to the College in writing on 4 August 2015.
The Committee decided that all four heads of charge amounted to disgraceful conduct in a professional respect as his actions contravened several sections of the Code of Professional Conduct for Veterinary Surgeons in relation to being open and honest with clients; keeping clear, accurate and detailed clinical records; and not engaging in any actions or behaviour that would likely bring the profession into disrepute or undermine public confidence in the profession.
The Committee noted that, in his statement, Mr Costelloe gave a number of reasons for his conduct, including concern over Mrs Green’s reaction to the death of her dog and concern for the young vet who was on duty when Scruffy died. However, the Committee considered that the need to be open and honest with his clients should have been put above the needs of his practice.
In considering its sanction against Mr Costelloe, the Committee heard mitigating evidence from four character witnesses called on his behalf, as well as a number of written testimonials, and also had regard to his evident remorse, shame and insight into his behaviour.
However, it also considered a number of aggravating factors, including the fact that the misconduct had premeditated elements, was sustained over a period of weeks, and constituted a clear breach of client trust.
The Committee decided that the most appropriate sanction was to suspend Mr Costelloe from the Register for a period of 10 weeks. Chitra Karve, chairing the Committee and speaking on its behalf, said: "It [the Committee] concluded that this was the appropriate and proportionate sanction in this case. The Committee took the view that the likelihood of repetition of dishonest conduct was very low. It had found no ‘attitude of dishonesty’ in the respondent. There were no risks to the welfare or health of animals. The respondent was a good veterinary surgeon and he had shown considerable insight regarding his dishonesty, for example, by actively seeking out Ms Green to tell her the truth.
"The Committee does not condone what the respondent has done. It considers that the public interest requires that there has to be confidence that veterinary surgeons do not fabricate accounts or documents, no matter what their intentions."
She added: "The Committee has therefore determined that suspension for a period of 10 weeks is proportionate in all the circumstances to mark the nature and gravity of the case and is sufficient to maintain public confidence in the profession and to uphold proper standards of conduct and behaviour, and directs the Registrar accordingly."
The Committee’s full findings and decision are available on the RCVS website (www.rcvs.org.uk/disciplinary).
The clinic will offer referrals in orthopaedics, internal medicine, soft tissue surgery, neurology and advanced imaging from a team which includes Rory Bell, an RCVS and European Recognised Specialist in Internal Medicine, and Jonathan Bell, an EBVS and RCVS Specialist in Small Animal Surgery.
The practice says it has some of the most advanced equipment in Europe, including a Siemens 128 slice CT scanner and a Siemens 1.5T Aera MRI scanner. The clinic also has three environmentally-controlled theatres, with CT and MRI scanning capabilities.
Dr Stuart Cooke BVetMed CertSAS MRCVS, one of Swift Referrals founders said: “We’re delighted to launch Swift Referrals, and would like to thank everyone who helped us get here. We are proud to be able to say that we house some of the most advanced equipment in the continent, from the very best advanced imaging machines, to specialist treatment and aftercare rooms. We also have some of the most skilled veterinary experts operating in them, day in and day out. Our clinicians are leaders in their field of expertise, with years of experience and very advanced training."
For more information: www.swiftreferrals.co.uk/.
Merck has announced that its animal health division, formerly known as Intervet/Schering-Plough, has changed its name to MSD Animal Health in countries outside the United States and Canada from today.
Intervet/Schering Plough will now be known as Merck Animal Health in the United States and Canada.
Raul Kohan, President of Merck Animal Health said: "The name change reflects Merck's commitment to animal health and its complementary role to the overall business. We are unwavering in our commitment to veterinarians, producers, pet owners and society as a whole. We aim to generate additional value and sustained growth by continuing to provide integrated solutions with innovative animal health products and services to meet the evolving needs of our customers."
Mr. Kohan continued: "With the scientific and business backing of Merck, Merck Animal Health possesses the necessary mix of resources to enhance our position as an industry leader."
Merck says it values the diversification that Merck Animal Health brings to its portfolio, and sees growth opportunities in the business that can be leveraged across both animal and human health. The company intends to capitalize on Merck Animal Health's broad and innovative portfolio going forward, and to develop the unit into a best-in-class global animal health leader.
The name change follows the joint announcement on March 22, 2011 by Merck and sanofi-aventis that ended plans to form a new animal health joint venture. Both companies mutually decided to discontinue their agreement primarily because of the increasing complexity of implementing the proposed transaction.
The company says the product is highly effective against common bacteria including Staphylococci, Clostridia, Corynebacteria and Streptococci, and gram-negative bacteria including Bacteroides spp, Pasteurellae, and Proteus spp.
Clavubactin is available in a range of dose strengths to treat all sizes of patient. It is presented as a doubly divisible tablet for accurate and flexible dosing and to help avoid the development of antibiotic resistance associated with under dosing. The tablets come in blister packs of 10, designed to help reduce unnecessary exposure when dispensing in practice.
Dechra Brand Manager Carol Morgan said: "The introduction of Clavubactin to our antibiotic portfolio will give veterinary professionals even more choice of effective and targeted treatments in their day-to-day practice."